MDNAFOTCPharmaceutical PreparationsFiscal year ends March 31

Medicenna Therapeutics Corp.

Financials through fiscal 2023, year ended Mar 31, 2023Last filing: 20-F on Jun 27, 2023

$0.28−0.02 (-7.63%)

Close on Oct 19, 2026

Medicenna Therapeutics Corp. income statement

Annual Quarterly TTM

CAD USD

Millions of CAD, except per-share data. Shares in millions.

Line item	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31
Research & Development	9.30	15	11	5.87
Operating Expenses	16	22	17	8.25
Pretax Income	-10	-23	-17	-8.28
Income Tax Expense	0	0	0	0
Net Income incl. Noncontrolling Interests	-10	-23	-17	-8.28
EPS (Basic)(per share)	-0.16	-0.42	-0.35	-0.26
EPS (Diluted)(per share)	–	–	-0.35	-0.26
Shares Outstanding (Basic, Weighted)(shares)	65	54	50	32
Shares Outstanding (Diluted, Weighted)(shares)	65	54	50	32

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2023

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2023: –

Financial strength

Current ratio: 9.57
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 884.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.